About: Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $63.40 (+3.09%)
SLGL NASDAQ Sol Gel Technologies Ltd
Sol Gel Technologies Ltd share price
Atividade de preço de SLGL
Último preço
$ 63,400
Variação (24h)
1,90 USD (3,09%)
Volume
13.51K
Volume (média 4 sem.)
-
Abertura
$ 62,99
Variação do dia
$ 62,01 - $ 63,72
Fechamento anterior
$ 61,50
Último negócio
11 Nov, 9:00 pm GMT+0
Atrasado
11 Nov, 9:00 pm GMT+0
SLGL price performance
Atrasado
11 Nov, 9:00 pm GMT+0
SLGL details
quote.marketSignals